1 badge
Premium

Dr Michael BENZAQUEN

Dermatologist
France

Dr. Michael Benzaquen completed medical education at the Faculty of Medicine of Marseille, Aix-Marseille University (Marseille, France), and ranked first among 3000 students in the first year of medical school. He then completed his residency in Dermatology at Assistance Publique Hôpitaux de Marseille, before a fellowship in the department of Dermatology at Hôpital Nord de Marseille. His professional experiences abroad in Columbia University (New York City, USA) and Inselspital - University Hospital of Bern (Bern, Switzerland) improved his clinical skills and knowledge in Dermatology, as well as his success in ECFMG certification. He graduated from several inter-university diplomas in Internal Medicine, Pediatric Dermatology, Dermatological Laser and Dermatological Surgery. As an active member of the French Society of Dermatology and the European Academy of Dermatology and Venereology, he is invited as speaker in many international congresses. His works have been published in international peer-reviewed journals. He notably investigated about infectious diseases with cutaneous manifestations (Dirofilariasis, Nocardiosis, syphilis, scabies), as well as systemic and inflammatory diseases (dermatomyositis, vasculitis, pyoderma gangrenosum, bullous pemphigoid). As a member of the French Laser Group, he encouraged young dermatologists in learning and practicing dermatological lasers.

read more
add item add Michael BENZAQUEN

Michael BENZAQUEN's publications (18)

Desensitization protocol for angioedema induced by encorafenib in a patient with metastatic melanoma.

Mar, 2019

Encorafenib is an oral BRAF kinase inhibitor used in patients with BRAFV600 mutated melanoma (1). Generalized hypersensitivity reactions (HSR) have been described with BRAF inhibitors (BRAFi) (2), but remain rare. Desensitization protocols to overcome HSR by gradual reintroduction of small amounts of the incriminating drug up to full therapeutic doses have been proposed for vemurafenib (3, 4) and dabrafenib (5), but not yet for encorafenib. We describe a successful desensitization protocol to encorafenib in a patient presenting with an encorafenib-induced angioedema. This article is protected by copyright. All rights reserved. read more

Journal of the European Academy of Dermatology and Venereology : JEADV

Cutaneous shrinkage after surgical resection of facial skin tumours: a prospective study on 100 surgical specimens.

Feb, 2019

read more

Clinical and experimental dermatology

Mucous membrane pemphigoid of the oral lichen type: a retrospective analysis of 16 cases.

Feb, 2019

read more

Journal of the European Academy of Dermatology and Venereology : JEADV
Load more  

Michael BENZAQUEN's learned societies (5)

Michael BENZAQUEN's main interests